Afruza Rownock, Minerva Nicole, Lack Justin B, Chakraborty Moumita, Haddad James A, Ali Rabab O, Koh Christopher, Levy Elliot B, Etzion Ohad, Heller Theo
Translational Hepatology Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Research Technologies Development Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Methods Protoc. 2023 Nov 20;6(6):112. doi: 10.3390/mps6060112.
Cell-free RNAs (cfRNAs) are promising analytes as non-invasive biomarkers and have even greater potential if tied in with metabolomics. Plasma is an optimal source for cfRNAs but is often derived from a variety of anticoagulants. Plasma obtained in heparin is suitable for metabolomics but is difficult to utilize for qPCR-based downstream analysis. In the present study, we aimed to develop a simple, time-efficient, and cost-effective heparinase protocol, followed by library preparation and sequencing of human plasma cfRNAs drawn and stored in heparin at -80 °C for several years. Blood was collected in CPT™ sodium heparin tubes from patients with chronic HCV infection (NCT02400216) at the National Institutes of Health (NIH) Clinical Center. Plasma cfRNAs were treated with heparinase I and used for library preparation and next-generation sequencing (NGS). Heparinase treatment maintained RNA integrity and allowed for successful library preparation for all the study subjects even with 7 ng of cfRNAs as starting material. The classification report derived from Pavian R package v1.2.0 showed no artificial reads. The abundance of chordate over microbial reads suggests no addition of experimental error through heparinase I treatment. We report a novel and practical approach to heparinase treatment for human plasma collected and frozen in sodium heparin for several years. This is an effective demonstration of utilizing heparin plasma for NGS and downstream transcriptomic research, which could then be integrated with metabolomics from the same samples, maximizing efficiency and minimizing blood draws.
无细胞RNA(cfRNAs)作为非侵入性生物标志物是很有前景的分析物,如果与代谢组学相结合则具有更大的潜力。血浆是cfRNAs的最佳来源,但通常来自多种抗凝剂。用肝素获得的血浆适用于代谢组学,但难以用于基于qPCR的下游分析。在本研究中,我们旨在开发一种简单、省时且经济高效的肝素酶方案,随后对在-80°C下用肝素采集并储存数年的人血浆cfRNAs进行文库制备和测序。血液从美国国立卫生研究院(NIH)临床中心的慢性丙型肝炎病毒(HCV)感染患者(NCT02400216)的CPT™ 肝素钠管中采集。血浆cfRNAs用肝素酶I处理,并用于文库制备和下一代测序(NGS)。即使以7 ng的cfRNAs作为起始材料,肝素酶处理仍能保持RNA完整性,并使所有研究对象成功进行文库制备。来自Pavian R软件包v1.2.0的分类报告显示没有人工读取序列。脊索动物序列相对于微生物序列的丰度表明,肝素酶I处理未增加实验误差。我们报告了一种新颖且实用的方法,用于处理在肝素钠中采集并冷冻数年的人血浆的肝素酶。这是利用肝素血浆进行NGS和下游转录组学研究的有效证明,然后可以将其与来自相同样本的代谢组学相结合,从而最大限度地提高效率并减少采血次数。